02/02/2012
Vertex reports fourth quarter and full year 2011 financial results
Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow.
Read the press release here.
Vertex Pharmaceuticals Incorporated
http://www.vrtx.com/
Share this page
DISCLAIMER
The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
More...
